KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors
Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021
Ended the quarter with cash and cash equivalents and investments of $383.1 million
Closed $35 million Series A financing of Chinese joint venture in May 2021
https://finance.yahoo.com/news/kinnate-biopharma-inc-reports-first-200500578.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.